Eight Years of Experience with Eculizumab in a Case of Paroxysmal Nocturnal Hemoglobinuria

PNH is caused by somatic mutations in the PIG-A gene, resulting in deficiency of glycosylphosphatidylinositol (GPI)-anchored complement-regulatory proteins (CD55, CD59) on blood cells. The loss of these proteins leads to uncontrolled terminal complement activation, chronic hemolysis, and serious complications including thrombosis, renal impairment, and diminished quality of life. Eculizumab, a humanized monoclonal antibody targeting C5, interrupts this cascade and has become the standard of care for patients with transfusion-dependent or life-threatening hemolysis. Long-term clinical efficacy and safety, however, require multi-year follow-up, particularly regarding sustained remission, risk of breakthrough hemolysis, and late adverse effects.

Demographics and Baseline

·        Patient: 38-year-old female diagnosed with classical PNH after six months of severe fatigue, hemoglobinuria, and recurrent abdominal pain.

·        Initial laboratory parameters: LDH 4150 IU/L (10.4 times upper limit of normal), hemoglobin 6.8g/dL, absolute reticulocyte count 320,000/μL, total bilirubin 3.2mg/dL, negative Coombs test.

·        Flow cytometry: 82% GPI-deficient (type III) granulocytes and erythrocytes.

·        History: Two prior thrombotic events (hepatic and portal vein thrombosis), chronic renal impairment (eGFR 64mL/min/1.73m^2).

·        Received regular transfusions (2–3 units red cells/month) and warfarin for thrombosis prophylaxis.

Eculizumab Initiation

·        Eculizumab started per standard protocol: 600mg IV weekly × 4 weeks, then 900mg IV every two weeks.

·        Pre-medication: Meningococcal vaccination administered prior to therapy.

Long-Term Follow-Up (Eight Years)

Hemolysis Control and Hematologic Parameters

·        Within three months: LDH normalized to <1.5× ULN, hemoglobin stabilized at 10–11g/dL without further transfusions.

·        Reticulocyte count and bilirubin markedly decreased; hemoglobinuria resolved.

·        The patient-maintained transfusion independence for the full eight years.

Thrombosis and Renal Function

·        No additional thrombotic events occurred after eculizumab initiation.

·        Progressive improvement in renal function: eGFR increased from 64 to 82mL/min/1.73m^2 by year six and remained stable.

Quality of Life and Symptom Management

·        Significant reduction in fatigue and abdominal pain; returned to full-time employment within one year.

·        Quality-of-life scores (FACIT-Fatigue) improved and remained above pre-disease baseline.

Breakthrough Hemolysis

·        Two episodes of breakthrough hemolysis associated with infections (influenza, bacterial sinusitis) occurred in years four and seven.

o   Both required temporary hospital admission, supportive care, and adjustment of eculizumab dosing interval.

o   Full stabilization achieved within two weeks; no transfusion required.

Safety and Tolerability

·        No major adverse effects related to eculizumab; mild headaches following infusion during the first year.

·        No meningococcal infection detected.

·        Laboratory monitoring: No evidence of clonal evolution or bone marrow failure.

Comparative Real-World Data

Table 1. Long-Term Outcomes From Major Series

Abbreviations: AEs, adverse events. Data are generalized based on published cohort statistics.

Clinical Course Graphs

Figure 1. LDH and Hemoglobin Trends Over Eight Years

·        LDH rapidly normalized following eculizumab initiation and remained stable except during breakthrough episodes.

·        Hemoglobin increased above transfusion threshold by month 2 and normalized within six months.

Figure 2. Survival and Transfusion Independence in Cohorts Treated With Eculizumab (Kaplan-Meier representation)

·        Survival rates at 3–5 years consistently close to the general population; transfusion independence maintained in over 60–80% depending on cohort^[1][2].

Efficacy

Eculizumab provided rapid and sustained control of intravascular hemolysis in PNH, resulting in transfusion independence, marked symptom improvement, and excellent renal function preservation over eight years. These findings are supported by cohort and registry studies, which demonstrate normalization of hemolysis markers (LDH), reduced thrombotic risk, improved survival, and substantial gains in quality of life^[1][2][7][4].

Breakthrough Events

While rare, breakthrough hemolysis episodes—often infection-related—occurred but were manageable with supportive care. Published series indicate 5–15% of patients may experience such events over prolonged follow-up^[5][2][7].

Safety, Risks, and Monitoring

Eculizumab was well tolerated without cumulative toxicity or discontinuations in this individual case; registry data confirm a favorable long-term safety profile, though vigilance for meningococcal infection and rare late-onset adverse effects remain essential.

Limitations and Real-World Nuances

Not all patients attain full hematological response; studies demonstrate ongoing anemia, breakthrough hemolysis, or transfusion needs in a minority, underscoring the importance of individualized management^[5][6].

Eight years of eculizumab therapy in this case resulted in dramatic and sustained clinical, hematologic, and functional improvement—achieving the current standard of care for PNH. Long-term data from larger studies corroborate this experience, supporting eculizumab as a transformative therapy for most patients with classical, complement-mediated PNH. Future monitoring, rare safety vigilance, and research on next-generation complement inhibitors will define ongoing and upcoming standards of care.

Figure 1. Longitudinal changes in LDH and hemoglobin over eight years of eculizumab therapy
Figure 2. Kaplan-Meier curves showing overall survival and transfusion independence rates in published PNH cohorts receiving eculizumab

1.      Hillmen, Peter, et al. "Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria." British Journal of Haematology, vol. 162, no. 1, 2013, pp. 62–73.

2.      Kelly, R. Jade, et al. "Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival." Blood, vol. 117, no. 25, 2011, pp. 6786–6792.

3.      Versmold, K., et al. "Long-term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real-world setting." European Journal of Haematology, 2023.

4.      Kim, Jae-Sun, et al. "Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea." Journal of Korean Medical Science, vol. 38, no. 52, 2023, e328.